
    
      This a prospective, single-arm, open-label, phase 2 studye evaluating the efficacy and safety
      of camrelizumab, gemcitabine and nab-paclitaxel for metastatic pancreatic cancer patients.
      The primary endpoints are ORR and PFS, and the secondary are OS and adverse events.
    
  